Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Cancer Tumor Profiling Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.
The global cancer tumor profiling market, a key sector in the medical diagnostics domain, is observing a remarkable growth trajectory. This detailed report sheds light on the comprehensive landscape of tumor profiling, which plays an instrumental role in the realm of cancer diagnostics and personalized medicine.
Highlighting the market dynamics, the report encapsulates pivotal data on the enlarged market size, which is anticipated to burgeon from $11.17 billion in 2023 to $12.93 billion in 2024, marking an impressive compound annual growth rate (CAGR) of 15.7%. Underpinning this surge is the increasing incidence of diverse cancer types and advances in precision medicine, entailing extensive research and development in diagnostic methodologies.
Within the detailed analysis, the cancer tumor profiling market research publication offers an exhaustive evaluation of various subsectors and their contributions to the industry growth. It meticulously examines lung, breast, colorectal, and prostate cancers, among others, alongside groundbreaking technologies such as Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), and Polymerase Chain Reaction (PCR).
Asia-Pacific: A High-Growth Epicenter in the Tumor Profiling Sector
The insights extend to geographic market shares, with a spotlight on Asia-Pacific as the fastest-growing region within the forecasting timeframe. Driven by escalating healthcare demand and the uptake of advanced diagnostic technologies, the Asian market represents a significant nexus of opportunities for medical research and therapeutic interventions.
Key market trends illuminated in the report include:
- The proliferation of immunotherapy and immunoprofiling applications, steering the evolution of cancer treatment paradigms.
- Groundbreaking developments in liquid biopsy and non-invasive profiling methodologies, fostering a new era of convenience and precision.
- The advent of single-cell sequencing, bolstering the intricacies of tumor characterization.
- Artificial intelligence (AI) and machine learning advancements, refining data analysis frameworks and predictive modeling.
- The rising demand for rare and orphan cancer subtype profiling, underpinning a patient-centric approach to oncology.
The publication uncovers the constellation of factors fueling the market's expansion, including clinical and technological innovations, and emphasizes significant corporate maneuvers shaping the landscape. It elaborates on the 2023 acquisition by Quest Diagnostics and Labcorp's 2021 strategic move, underscoring the competitive fervor characterizing the industry.
Comprehensive Analysis of Leading Entities in Tumor Profiling
Featured in the report is a comprehensive delineation of prominent market players, including renowned international firms such as F. Hoffmann-La Roche Ltd., Illumina Inc., and Thermo Fisher Scientific Inc. The document showcases company profiles, portfolio capabilities, and recent developments, delivering a holistic understanding of the cancer tumor profiling ecosystem.
The full research findings offer a forward-looking perspective on the cancer tumor profiling industry, highlighting crucial market indicators, emergent trends, and geographical analyses crucial for comprehending the current and future market scenario. This vital resource is an indispensable tool for those aiming to stay ahead of the curve in the dynamic and evolving landscape of cancer diagnostics and individualized treatment solutions.
Companies Profiled
- F. Hoffmann-La Roche Ltd.
- Caris Life Sciences
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Qiagen
- Ribomed Biotechnologies Inc.
- HTG Molecular Diagnostics Inc.
- NanoString Technologies Inc.
- NeoGenomics Laboratories Inc.
- Lucence Health Inc.
- ACT Genomics Co. LTD
- Strand Life Sciences
- IMB Dx Inc.
- Exact Sciences Corporation
- Guardant Health
- Foundation Medicine Inc.
- Agilent Technologies Inc.
- Myriad Genetics Inc.
- Personal Genome Diagnostics Inc.
- Tempus Labs Inc.
- ArcherDX Inc.
- Natera Inc.
- Bio-Rad Laboratories Inc.
- Genetron Health
- NantHealth Inc.
- Resolution Bioscience
- Genomic Testing Cooperative
- OncoDNA
- Strata Oncology Inc.
- Genuity Science
- RareCyte Inc.
- Inivata Limited
- Cepheid
For more information about this report visit https://www.researchandmarkets.com/r/3kxbe
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
